Biovie Competitors
| BIVI Stock | USD 1.26 0.02 1.56% |
Biovie vs Lipella Pharmaceuticals Correlation
Poor diversification
The correlation between Biovie Inc and LIPO is 0.62 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Biovie Inc and LIPO in the same portfolio, assuming nothing else is changed.
Moving against Biovie Stock
| 0.75 | DRTS | Alpha Tau Medical | PairCorr |
| 0.7 | EQ | Equillium | PairCorr |
| 0.66 | 6C1 | CytomX Therapeutics | PairCorr |
| 0.64 | GXEA | Galapagos NV Earnings Call This Week | PairCorr |
| 0.63 | 8VP1 | AVRICORE HEALTH INC | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Biovie's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Biovie Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Biovie and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Biovie and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Biovie Inc does not affect the price movement of the other competitor.
Risk-Adjusted Indicators
There is a big difference between Biovie Stock performing well and Biovie Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Biovie's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| KZIA | 8.35 | 0.10 | 0.02 | 0.06 | 10.28 | 14.69 | 78.79 | |||
| ELAB | 6.00 | (4.01) | 0.00 | (1.03) | 0.00 | 7.40 | 53.38 | |||
| CANF | 5.14 | (0.57) | 0.00 | 0.39 | 0.00 | 10.40 | 38.42 | |||
| CERO | 6.94 | (0.86) | 0.00 | (0.28) | 0.00 | 14.29 | 49.80 | |||
| TOVX | 5.72 | (0.55) | 0.00 | (0.11) | 0.00 | 10.53 | 38.10 | |||
| GLMD | 4.24 | (0.92) | 0.00 | (0.57) | 0.00 | 9.33 | 21.39 | |||
| OCEA | 46.60 | 16.80 | 0.46 | (2.89) | 27.77 | 160.00 | 473.33 | |||
| ARTL | 4.62 | (0.45) | 0.00 | (3.40) | 0.00 | 7.30 | 41.63 | |||
| INM | 4.38 | (0.95) | 0.00 | (0.64) | 0.00 | 7.48 | 30.84 | |||
| LIPO | 8.24 | (0.53) | 0.00 | (0.44) | 0.00 | 17.65 | 94.73 |
Cross Equities Net Income Analysis
Compare Biovie Inc and related stocks such as Kazia Therapeutics, Elevai Labs Common, and Can Fite Biopharma Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KZIA | (17.1 M) | 1.3 M | (1 M) | (7.5 M) | (7.1 M) | (12.1 M) | (10.7 M) | (6 M) | (10.3 M) | (12.5 M) | (8.4 M) | (25 M) | (20.5 M) | (26.8 M) | (20.7 M) | (23.8 M) | (25 M) |
| ELAB | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (784.7 K) | (1.8 M) | (4.3 M) | (6.2 M) | (5.6 M) | (5.3 M) |
| CANF | (3.7 M) | (6.7 M) | (5.6 M) | (8.3 M) | (6.1 M) | (4.8 M) | (6.9 M) | (5 M) | (6.6 M) | (12.6 M) | (14.4 M) | (12.6 M) | (10.2 M) | (7.6 M) | (7.9 M) | (7.1 M) | (7.4 M) |
| CERO | (315.5 K) | (315.5 K) | (315.5 K) | (315.5 K) | (315.5 K) | (315.5 K) | (315.5 K) | (315.5 K) | (315.5 K) | (315.5 K) | (315.5 K) | (315.5 K) | (667.7 K) | (2.5 K) | (7.7 M) | (7 M) | (6.6 M) |
| TOVX | (3.9 M) | (8.1 M) | (17.1 M) | (12.3 M) | (19.8 M) | (43.7 M) | (27.3 M) | (15.2 M) | (13.4 M) | (15.3 M) | (10 M) | (14.2 M) | (19.7 M) | (18.3 M) | (25.7 M) | (23.1 M) | (21.9 M) |
| GLMD | (3.1 M) | (3.1 M) | (3.1 M) | (17.5 M) | (9.1 M) | (10.6 M) | (17 M) | (12.3 M) | (9.9 M) | (18.5 M) | (27.6 M) | (31.9 M) | (18.6 M) | (6.9 M) | (7.5 M) | (6.8 M) | (7.1 M) |
| ARTL | (15.3 K) | (15.3 K) | (15.3 K) | (15.3 K) | (15.3 K) | (15.2 K) | (29.7 K) | (234.9 K) | (2.3 M) | (2.2 M) | (4.7 M) | (7.4 M) | (10.1 M) | (9.3 M) | (9.8 M) | (8.8 M) | (8.4 M) |
| INM | (4.3 M) | (189.9 K) | (46.7 K) | (1.2 M) | (3.5 M) | (1.8 M) | (3.4 M) | (6.7 M) | (10 M) | (8.9 M) | (12.6 M) | (18.6 M) | (7.9 M) | (7.7 M) | (8.2 M) | (7.3 M) | (7 M) |
| LIPO | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.7 K) | (1.9 M) | (2.6 M) | (4.6 M) | (5 M) | (4.5 M) | (4.3 M) |
Biovie Inc and related stocks such as Kazia Therapeutics, Elevai Labs Common, and Can Fite Biopharma Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Biovie Inc financial statement analysis. It represents the amount of money remaining after all of Biovie Inc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Biovie Competitive Analysis
The better you understand Biovie competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Biovie's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Biovie's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Biovie Competition Performance Charts
Five steps to successful analysis of Biovie Competition
Biovie's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Biovie Inc in relation to its competition. Biovie's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Biovie in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Biovie's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Biovie Inc, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Biovie position
In addition to having Biovie in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Railroads Thematic Idea Now
Railroads
Companies involved in manufacturing and maintenance of freight railroads and passenger trains as well as providing railroad services to public. The Railroads theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Railroads Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Biovie Correlation with its peers. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is there potential for Biotechnology market expansion? Will Biovie introduce new products? Factors like these will boost the valuation of Biovie. Projected growth potential of Biovie fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Biovie listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Understanding Biovie Inc requires distinguishing between market price and book value, where the latter reflects Biovie's accounting equity. The concept of intrinsic value - what Biovie's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Biovie's price substantially above or below its fundamental value.
It's important to distinguish between Biovie's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biovie should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biovie's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.